Axsome Therapeutics

CNS Pipeline Advancements Will Expand Global Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 Apr 25

Updated

01 May 25

AnalystConsensusTarget's Fair Value

US$176.84

26.7% undervalued

04 Sep

US$129.58

44.0%

9.2%

44.0%

9.2%

You can edit this narrative until May 12 5:58 AM. Then, changes will post as Updates.

Author's Valuation

US$176.8426.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 0.03%

AnalystConsensusTarget Fair Value

US$176.84

26.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

33.24%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$553.34m

Earnings '28

21.01x

PE Ratio '28

US$11.63b

Market Cap '28

US$11.63b

Market Cap '28

54.48m

No. shares '28

US$213.38

Share Price '28

US$213.38 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$175.28

Fair Value '25

CNS Pipeline Advancements Will Expand Global Reach

Shared on01 May 25Fair value Increased 0.03%

Shared on01 May 25
Fair value Increased 0.03%